Funding Opportunity RFA-AG-23-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for projects designed to understand molecular and cellular mechanisms underlying cerebral blood flow reduction in Alzheimers disease (AD) and Alzheimers disease-related dementias (ADRD).

Notice NOT-DE-22-006 from the NIH Guide for Grants and Contracts

Competitive Rate : CY Partners: Support & inform the analysis of the oncology NGS dataset & guide the development of the data analysis pipeline for clinical variant identification. London (Greater) (GB)

Funding Opportunity PAR-22-000 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIBIB R25 program is to support educational activities thatcomplement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development.This FOA seeks to support programs that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nations needs in biomedical research and healthcare technologies. Applications are encouraged from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate biomedical engineering departments or other degree-granting programs with biomedical engineering tracks/minors. This FOA targets the education of undergraduate biomedical engineering/bioengineering students in a team-based environment. While current best practices such as multidisciplinary/interdisciplinary education, introduction to the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion remain encouraged components of a strong BME program, this FOA also challenges institutions to propose other novel, innovative and/or ground-breaking activities that can form the basis of the next generation of biomedical engineering design education.

highly competitive salary and benefits package: Astex Pharmaceuticals: Astex Pharmaceuticals is a world leader in innovative drug discovery and development. Cambridge, Cambridgeshire

Basic computational and bioinformatic skills (R, Python, MS Word, MS Excel, Adobe Illustrator). Execute data analysis using internal/external software (e.g. Web… $5,457 - $6,250 a month
From University of Washington - Sat, 19 Feb 2022 05:40:39 GMT - View all Seattle, WA jobs

Funding Opportunity RFA-RM-22-001 from the NIH Guide for Grants and Contracts. The Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and advancing health equity.

Notice NOT-DA-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-056 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-078 from the NIH Guide for Grants and Contracts

Notice NOT-DC-22-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-086 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. The R21 FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy, imaging, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy.

Funding Opportunity PAR-22-085 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy. (link to OCCAM)

Experience with gene expression analyses, computational biology, genomics and bioinformatics desired. Knowledge of current technological developments/trends…
From Medical College of Wisconsin - Fri, 18 Feb 2022 03:13:55 GMT - View all Milwaukee, WI jobs

Notice NOT-OD-22-049 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-055 from the NIH Guide for Grants and Contracts

Notice NOT-HS-22-010 from the NIH Guide for Grants and Contracts

Notice NOT-TR-22-018 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-001 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-23-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD.This FOA will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.